BIG1 Fundamental Analysis - BIO-GATE AG

Name: BIO-GATE AG (BIG1) Stock
Brand: BIO-GATE AG
Rating: 4 (3 reviews)

Fundamental Rating

Overall BIG1 gets a fundamental rating of 3 out of 10. We evaluated BIG1 against 67 industry peers in the Chemicals industry. BIG1 scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BIG1 is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

BIG1 had negative earnings in the past year.

In the past year BIG1 has reported a negative cash flow from operations.

BIG1 had negative earnings in each of the past 5 years.

In the past 5 years BIG1 always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -32.97%, BIG1 is doing worse than 89.39% of the companies in the same industry.

The Return On Equity of BIG1 (-151.10%) is worse than 89.39% of its industry peers.

		Industry Rank	Sector Rank
ROA	-32.97%
ROE	-151.1%
ROIC	N/A

ROA(3y)-33.66%

ROA(5y)-27.14%

ROE(3y)-61.46%

ROE(5y)-50.16%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BIG1 has a better Gross Margin (57.72%) than 87.88% of its industry peers.

BIG1's Gross Margin has declined in the last couple of years.

BIG1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	57.72%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.52%

GM growth 5Y-2.6%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BIG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.

BIG1 has about the same amout of shares outstanding than it did 1 year ago.

BIG1 has more shares outstanding than it did 5 years ago.

There is no outstanding debt for BIG1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

BIG1 has an Altman-Z score of -2.58. This is a bad value and indicates that BIG1 is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of BIG1 (-2.58) is worse than 89.39% of its industry peers.

There is no outstanding debt for BIG1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.58

ROIC/WACCN/A

WACC7.33%

2.3 Liquidity

A Current Ratio of 1.85 indicates that BIG1 should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.85, BIG1 is in line with its industry, outperforming 54.55% of the companies in the same industry.

A Quick Ratio of 0.55 indicates that BIG1 may have some problems paying its short term obligations.

BIG1 has a Quick ratio of 0.55. This is amonst the worse of the industry: BIG1 underperforms 90.91% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.85
Quick Ratio	0.55

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.80% over the past year.

The Revenue has decreased by -7.53% in the past year.

BIG1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.13% yearly.

EPS 1Y (TTM)31.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.52%

Revenue 1Y (TTM)-7.53%

Revenue growth 3Y4.19%

Revenue growth 5Y15.13%

Sales Q2Q%-2.1%

3.2 Future

The Earnings Per Share is expected to grow by 23.39% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 16.89% on average over the next years. This is quite good.

EPS Next Y39.39%

EPS Next 2Y26.73%

EPS Next 3Y23.39%

EPS Next 5YN/A

Revenue Next Year13.3%

Revenue Next 2Y13.28%

Revenue Next 3Y16.89%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BIG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BIG1 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BIG1's earnings are expected to grow with 23.39% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.73%

EPS Next 3Y23.39%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BIG1!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIO-GATE AG

FRA:BIG1 (11/6/2025, 7:00:00 PM)

0.77

-0.03 (-3.75%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)10-03 2025-10-03

Earnings (Next)02-18 2026-02-18

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners9.8%

Ins Owner ChangeN/A

Market Cap7.11M

Revenue(TTM)6.98M

Net Income(TTM)-1.38M

Analysts85.71

Price Target3.21 (316.88%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)16.67%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.02
P/FCF	N/A
P/OCF	N/A
P/B	7.8
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.07

Fwd EYN/A

FCF(TTM)-0.09

FCFYN/A

OCF(TTM)-0.08

OCFYN/A

SpS0.76

BVpS0.1

TBVpS-0.01

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-32.97%
ROE	-151.1%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	57.72%
FCFM	N/A

ROA(3y)-33.66%

ROA(5y)-27.14%

ROE(3y)-61.46%

ROE(5y)-50.16%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.52%

GM growth 5Y-2.6%

F-Score4

Asset Turnover1.67

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	30.72%
Cap/Sales	1.35%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.85
Quick Ratio	0.55
Altman-Z	-2.58

F-Score4

WACC7.33%

ROIC/WACCN/A

Cap/Depr(3y)91.79%

Cap/Depr(5y)118.01%

Cap/Sales(3y)3.64%

Cap/Sales(5y)4.33%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)31.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.52%

EPS Next Y39.39%

EPS Next 2Y26.73%

EPS Next 3Y23.39%

EPS Next 5YN/A

Revenue 1Y (TTM)-7.53%

Revenue growth 3Y4.19%

Revenue growth 5Y15.13%

Sales Q2Q%-2.1%

Revenue Next Year13.3%

Revenue Next 2Y13.28%

Revenue Next 3Y16.89%

Revenue Next 5YN/A

EBIT growth 1Y30.26%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year59.6%

EBIT Next 3Y31.41%

EBIT Next 5YN/A

FCF growth 1Y65.31%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y66.93%

OCF growth 3YN/A

OCF growth 5YN/A

BIO-GATE AG / BIG1.DE FAQ

What is the fundamental rating for BIG1 stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIG1.DE.

What is the valuation status of BIO-GATE AG (BIG1.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO-GATE AG (BIG1.DE). This can be considered as Overvalued.

How profitable is BIO-GATE AG (BIG1.DE) stock?

BIO-GATE AG (BIG1.DE) has a profitability rating of 1 / 10.

What is the earnings growth outlook for BIO-GATE AG?

The Earnings per Share (EPS) of BIO-GATE AG (BIG1.DE) is expected to grow by 39.39% in the next year.

BIO-GATE AG (BIG1.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BIO-GATE AG / BIG1.DE FAQ

What is the fundamental rating for BIG1 stock?

What is the valuation status of BIO-GATE AG (BIG1.DE) stock?

How profitable is BIO-GATE AG (BIG1.DE) stock?

What is the earnings growth outlook for BIO-GATE AG?